The efficacies of daptomycin, teicoplanin, and vancomycin were compared in the therapy of experimental Staphylococcus aureus endocarditis. Rabbits infected with either of two methicillin-susceptible strains (SA-12871 
Daptomycin (LY146032) is the first of a new class of antimicrobial agents, the lipopeptides. This drug possesses excellent in vitro activity against a broad range of grampositive bacteria and has a spectrum of activity similar to those of the glycopeptide antimicrobial agents vancomycin and teicoplanin (5, 7) . However, the mechanism by which daptomycin inhibits and kills susceptible bacteria differs from those of the glycopeptides, and the drug maintains good activity against strains that are resistant to these agents (9, 11, 12, 15, 18) .
The in vivo activity of daptomycin against selected grampositive pathogens has been evaluated by using a variety of animal models and has been found to be generally good, but at times somewhat variable compared with conventional therapeutic regimens (2, 3, 10, 13, 17) . The efficacy of daptomycin in the treatment of serious gram-positive infections in humans has been shown to be less than satisfactory at a dosage level of 2 mg/kg of body weight per day (6; personal communication, Eli Lilly and Co., Indianapolis, Ind.). These unsatisfactory clinical results may have been secondary to the low dosage that was used; when combined with the extensive protein binding of daptomycin (>90%; see below), this low dosage would have resulted in low concentrations of free and biologically active drug. The use of higher doses may be adequate to overcome this problem. We investigated this possibility by comparing the therapeu-tic activities of higher-dose daptomycin with those of van- comycin and two dosage levels of teicoplanin (another highly protein-bound drug [1]) by using the rabbit model of Staphylococcus aureus endocarditis. We also determined the frequencies at which test strains developed diminished susceptibility to daptomycin and teicoplanin during therapy.
MATERIALS AND METHODS
Organisms. The strains of S. aureus used in this study were isolates from the bloodstreams of patients with endocarditis. MRSA-494 was a methicillin-resistant S. aureus strain, and SA-12871 was a methicillin-susceptible strain. Strain SA-12873 was a derivative of SA-12871 that was isolated from a patient who received teicoplanin for treatment of endocarditis. The organism was significantly less susceptible to teicoplanin than the parent strain was. Additional characteristics of this organism have been described elsewhere (9) .
In vitro studies. The MICs and MBCs of nafcillin, daptomycin, vancomycin, and teicoplanin for SA-12871, SA-12873, and MRSA-494 were determined by a microdilution method by using cation-adjusted Mueller-Hinton broth (CAMHB; Difco Laboratories, Detroit, Mich.) and a 1:1 combination of CAMHB and pooled normal rabbit serum (GIBCO BRL, Grand Island, N.Y.) (14) . The agar dilution technique also was used to determine the MICs of daptomycin, vancomycin, and teicoplanin for each test strain (14) .
These data were used in the determination of spontaneous mutation frequencies (see below).
The frequencies at which test strains developed spontaneous mutational resistance to 2-, 5-, and 10-fold the daptomy- h (for daptomycin and vancomycin) or 12 to 14 h (for teicoplanin) following the final dose and were autopsied in an aseptic manner. A terminal blood sample for culture was obtained, and vegetations and 500-mg (mean weight, representing approximately 20% of the organ) sections of the left kidney and spleen were removed for culture. These specimens were weighed, suspended in 0.85% NaCl (final volume, 1 ml), and homogenized. Quantitative bacterial counts, which were determined by serial dilution and plating techniques, were expressed as the log1o CFU per gram (sensitivity limit, 10 CFU per vegetation or tissue section). The effect of antibiotic carry-over on cultured material was minimized by the volume of agar used in culture plates. This dilution effect was at least 150-fold. Culture-negative specimens were considered to contain 10 CFU for numerical purposes and for comparison with other treatment regimens by one-way analysis of variance. Such specimens were considered "sterile" for comparison with other treatment regimens by use of the Fisher exact test (see below).
Antibiotic content in serum. Daptomycin concentrations in serum were determined by bioassay by using an agar well diffusion method (16) 0.49, P < 0.001; control, 2.92 ± 0.52, P < 0.001), possibly due, in part, to the small number of animals in this group. There were no differences between rabbits that received daptomycin, teicoplanin-HD, vancomycin, or no treatment (controls). The concentrations achieved in serum with each of the treatment regimens are given in Table 2 . There were no differences in the frequencies of blood culture sterilization after 2 or 4 days of therapy with daptomycin, teicoplanin-HD, teicoplanin-LD (excluding MRSA-494), or vancomycin in animals infected with SA-12871 or MRSA-494. Regardless of the treatment regimen used, 93 to 100% of rabbits had sterile cultures at both of these times. For rabbits infected with SA-12873, 88 to 94% had sterile blood cultures after 2 and 4 days of therapy with daptomycin, teicoplanin-HD, or vancomycin. The teicoplanin-LD regimen was as effective as the other regimens after 2 days of therapy (67% of blood cultures were sterilized), but after 4 days it was inferior to teicoplanin-HD (50 versus 94%, respectively; P < 0.05). Quantitative bacterial counts found in vegetations and tissues are given in Table 3 . Only a single animal (infected with SA-12871 and treated with daptomycin) died before completion of the 4-day treatment course (see below). For rabbits infected with SA-12871 or MRSA-494, there were highly significant reductions in bacterial counts compared with those for untreated controls at each site from which samples were taken for culture for all treatment regimens (P < 0.001). For animals infected with SA-12873, treatment with daptomycin, teicoplanin-HD, or vancomycin significantly reduced bacterial counts at all sites (P < 0.001). Treatment with teicoplanin-LD reduced bacterial counts in kidneys (P < 0.002) and spleens (P < 0.02), but not in vegetations (P > 0.05).
For animals infected with SA-12871, daptomycin was as effective as teicoplanin-HD and was more effective than teicoplanin-LD or vancomycin (P < 0.02) in reducing vegetation bacterial counts. There were no differences between daptomycin, teicoplanin-HD, or vancomycin for other sites from which samples were taken for culture or for animals infected with SA-12873 or MRSA-494. The teicoplanin-LD regimen was inferior to the daptomycin regimen in lowering vegetation bacterial counts in animals infected with SA-12873 (P < 0.005); compared with teicoplanin-HD and vancomycin, statistical significance was not achieved (P = 0.06 for both). With respect to renal tissue, the teicoplanin-LD regimen was inferior to the daptomycin (P < 0.05) and vancomycin (P < 0.01) regimens. This regimen was inferior to all other treatment regimens in reducing splenic bacterial counts (P < 0.005 versus daptomycin and teicoplanin-HD and P < 0.02 versus vancomycin).
Daptomycin was superior to teicoplanin-HD (P = 0.04), teicoplanin-LD (P = 0.008), and vancomycin (P = 0.004) in sterilizing vegetations of rabbits with SA-12871 endocarditis. There were no differences between treatment regimens with respect to sterilization of renal or 3.01 ± 1.56 (14) 1.27 ± 0.52 (17) 1.44 ± 0.61 (17) None (control) 10 8.79 ± 0.89 (0) 5.65 ± 1.86 (0) 5.37 ± 0.80 (0) a Values in parentheses are the number of culture-negative (sterile) specimens.
tissue (P = 0.01). All regimens were equivalent with respect to sterilization of each of the sites from which samples were taken for culture in animals infected with MRSA-494. In vivo development of resistance. Isolates of SA-12871 for which there were two-to fourfold rises in the teicoplanin MICs were recovered from the vegetations of 3 of 9 rabbits treated with teicoplanin-LD and 1 of 16 rabbits treated with teicoplanin-HD. These organisms made up 0.0006 to 0.003 and 81% of organisms recovered from the vegetations of animals treated with teicoplanin-LD and teicoplanin-HD, respectively. Isolates for which there were four-to eightfold rises in the daptomycin MICs were recovered from 2 of 16 rabbits treated with that drug. One of these animals died after receiving 10 of a planned 12 doses; postmortem examination demonstrated a persistence of organisms in blood, vegetations, and tissues. Blood and vegetation material yielded the resistant organisms, and resistant isolates made up the majority of the bacteria recovered from these sites. For the second animal, a single isolate for which there was a fourfold rise in the daptomycin MIC was recovered from vegetation material (0.008% of the total number of CFU recovered from that site). All isolates of SA-12871 for which there were rises in the daptomycin or teicoplanin MICs were recovered from plates containing 5-to 10-fold the MIC for the organism, but few maintained the expected degree of resistance after a single passage in antibiotic-free medium. The increments in MICs reported above were stable following several such passages.
No increases in daptomycin or teicoplanin MICs were found for posttherapy isolates of SA-12873 or MRSA-494.
DISCUSSION
Glycopeptide antimicrobial agents are useful alternatives to P-lactams in patients with infections caused by such organisms as methicillin-resistant staphylococci or P-lactamase-producing enterococci or in those patients who have significant 3-lactam allergies. Based on its spectrum of activity and results of animal studies, it appeared to be likely that the lipopeptide daptomycin would perform in a similar fashion. Daptomycin possesses an advantage over the glycopeptides in that it maintains good activity against strains resistant to vancomycin and teicoplanin (9, 11, 12, 15, 18) . However, as with teicoplanin, early data from human trials have been disappointing (4, 6) . Because of the highly protein-bound nature of both drugs, inadequate dosing in these trials may have been the main reason for the unsatisfactory results that were observed. In the current study we used doses of teicoplanin that produced levels in serum similar to those being achieved during therapy of serious systemic human staphylococcal infections (personal communication, Merrell-Dow Research Institute, Cincinnati, Ohio) and a dose of daptomycin that produced peak levels in serum moderately above those targeted for humans (40 to 60 ,ug/ml at the end of infusion; personal communication, Eli Lilly and Co.). We found that compared with untreated control animals, all treatment regimens that we used (including teicoplanin-LD) significantly reduced bacterial counts in vegetations and tissues of rabbits infected with SA-12871 or MRSA-494. With the exception of the teicoplanin-LD regimen, the same was true for animals infected with SA-12873, the moderately teicoplanin-resistant strain. In this case the teicoplanin-LD regimen likely failed because of the low concentration achieved in serum, which, when combined with the extensive protein binding of teicoplanin, resulted in free drug levels below the MIC for the organism throughout the dosing interval. Indeed, even in the presence of only 50% serum, we found that the teicoplanin MIC 
